文献速递肝病

代谢相关脂肪性肝病新定义对疾病流行病学的影响

Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-31

MAFLD定义为肝内甘油三酯含量≥5%且存在超重/肥胖、糖尿病或两项其他代谢危险因素,不要求排除其他肝病;NAFLD则需排除其他肝病。结果显示MAFLD与NAFLD患病率相近(25.9% vs 25.7%),但MAFLD可能使发病率降低25%。

要点

  • MAFLD新定义下患病率与NAFLD相近,但可能使发病率降低25%
  • 肝脂肪变但不符合MAFLD代谢标准者, unlikely有显著肝病
  • 多数NAFLD事件病例(75.6%)符合MAFLD标准

核心结论

  • MAFLD新定义与NAFLD相比患病率无显著变化,但可能使发病率降低25%。
  • 有肝脂肪变但不符合MAFLD定义者不太可能有显著肝病。

研究设计与样本

  • 从香港人口普查数据库随机选取1013名成人进行临床评估、质子磁共振波谱和瞬态弹性成像。

主要发现

  • MAFLD和NAFLD的总体患病率分别为25.9%(95% CI 23.2-28.7%)和25.7%(95% CI 23.1-28.5%)。
  • 在277名肝内甘油三酯含量≥5%的受试者中,247名(89.2%)同时符合MAFLD和NAFLD定义。
  • MAFLD发病率为2.8/100人年,中位随访间隔47个月(范围34-60个月)。
  • 在78名新发NAFLD受试者中,59名(75.6%)符合MAFLD标准;其中仅1名规律饮酒者肝脏硬度≥10 kPa。

关键数值与推荐

  • MAFLD诊断标准:肝内甘油三酯含量≥5%且存在超重/肥胖、糖尿病或两项其他代谢危险因素,伴或不伴其他肝病。
  • NAFLD诊断标准:需排除其他肝病,不考虑代谢因素。

临床怎么用

  • 在临床实践中采用MAFLD新定义可识别代谢相关脂肪肝患者,且可能降低发病率估计。
  • 对于肝脂肪变但不符合MAFLD代谢标准者,显著肝病风险较低,可减少不必要的进一步检查。

局限性

  • 研究人群为香港成人,结果外推需谨慎。
  • 随访中位间隔47个月,长期影响需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with modified diagnostic criteria. We aimed to study the impact of the new definition on the epidemiology of fatty liver disease. METHODS: We randomly selected 1013 adults from the Hong Kong census database for clinical assessment, proton-magnetic resonance spectroscopy, and transient elastography. Five hundred sixty-five subjects without fatty liver at baseline underwent follow-up assessment. MAFLD was diagnosed as intrahepatic triglyceride content (IHTG) ≥5% and the presence of overweight/obesity, diabetes, or two other metabolic risk factors, with and without concomitant liver diseases. The diagnosis of NAFLD required the exclusion of concomitant liver diseases; metabolic factors were not considered. RESULTS: The population prevalence of MAFLD and NAFLD was 25.9% (95% CI 23.2-28.7%) and 25.7% (95% CI 23.1-28.5%), respectively. Among 277 subjects with IHTG ≥5%, 247 (89.2%) fulfilled both the definitions of MAFLD and NAFLD. Fourteen subjects (5.1%) had IHTG ≥5% but did not meet the metabolic criteria of MAFLD. The incidence of MAFLD was 2.8 per 100 person-years at a median interval of 47 months (range 34-60 months). Among 78 subjects with incident NAFLD, 59 (75.6%) met the criteria of MAFLD; only one of the latter, a regular drinker, had liver stiffness ≥10 kPa. CONCLUSIONS: The new definition of MAFLD does not significantly change the prevalence compared with NAFLD, but it may reduce the incidence by 25%. People with hepatic steatosis but not fulfilling the definition of MAFLD unlikely have significant liver disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong VW, Wong GL, Woo J, et al. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol. 2020. PMID: 33137486. doi:10.1016/j.cgh.2020.10.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。